Prognostic significance of ras/p21 alterations in human ovarian cancer
- 1 May 1997
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 75 (10) , 1547-1553
- https://doi.org/10.1038/bjc.1997.264
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Oncogene Protein Co-Expression Value of Ha-ras, c-myc, c-fos, and p53 as Prognostic Discriminants for Breast CarcinomaAnnals of Surgery, 1995
- Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeuticCell, 1994
- Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancerInternational Journal of Gynecologic Cancer, 1993
- Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-upInternational Journal of Gynecologic Cancer, 1993
- ras oncogene product p21 expression and prognosis of human ovarian tumorsGynecologic Oncology, 1992
- Doxorubicin and Cyclophosphamide, Alternated with Bleomycin and Mitomycin C as a Second-Line Regimen in Advanced Ovarian Carcinoma Resistant to Cisplatin-Based ChemotherapyOncology, 1990
- Co-regulation of metastatic and transforming activity of normal and mutantras genesInternational Journal of Cancer, 1989
- Mutations of the Kirsten-ras proto-oncogene in human preleukaemiaNature, 1987
- Expression of Cellular Oncogenes in Human MalignanciesScience, 1984
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976